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Edited by Maurice MontalAbstract Regulation of Na+-dependent glutamate transport
was studied in isolated luminal and abluminal plasma membranes
derived from the bovine blood–brain barrier. Abluminal mem-
branes have Na+-dependent glutamate transporters while luminal
membranes have facilitative transporters. This organization
allows glutamate to be actively removed from brain. c-Glutamyl
transpeptidase, the ﬁrst enzyme of the c-glutamyl cycle (GGC), is
on the luminal membrane. Pyroglutamate (oxoproline), an intra-
cellular product of GGC, stimulated Na+-dependent transport of
glutamate by 46%, whereas facilitative glutamate uptake in lumi-
nal membranes was inhibited. This relationship between GGC
and glutamate transporters may be part of a regulatory mecha-
nism that accelerates glutamate removal from brain.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The blood–brain barrier (BBB) is formed by endothelial cells
of the cerebral capillaries that are joined by extensive tight
junctions and are, therefore, polarized [1]. Hydrophilic nutri-
ents, such as amino acids (AA), require the presence of carriers
in both the luminal and abluminal membranes to traverse the
BBB. Carriers in the luminal membrane are facilitative, while
the abluminal membrane has several Na+-dependent carriers
in addition to some facilitative carriers [1]. This distribution
of carriers may explain why the concentrations of all AA (ex-
cept glutamine) are lower in brain extracellular ﬂuid (ECF)
compared with plasma [2].
Glutamate, an excitatory AA, is toxic to the brain at very
low concentrations (>1–3 lM) [3–5]. At least three members
of the excitatory AA transport (EAAT) family are located in
the abluminal membrane of the BBB (EAAT-1, EAAT-2 and
EAAT-3) [6]. These transporters are Na+-dependent and can
actively remove glutamate from the ECF. Facilitative trans-
port of glutamate exists only on the luminal membrane, there-
by allowing glutamate to exit to the circulation [7]. This*Corresponding author. Fax: +1 847 775 6510.
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tions of glutamate within brain ECF [2].
While the organization of the BBB provides a mechanism
for active removal of AA as well as maintenance of their low
ECF concentrations, the regulation of these systems is undeter-
mined. Vin˜a et al. showed that intracellular pyroglutamate
stimulated Na+-dependent AA transporters located in mam-
mary glands and placentas of pregnant rats [8,9]. Pyrogluta-
mate, (also known as oxoproline – the cyclized amide of
glutamate), is produced within cells through the action of the
c-glutamyl cycle (GGC).
The GGC was proposed to be directly involved in AA trans-
port, but this suggestion has been controversial. Meister et al.
noted that c-glutamyl transpeptidase (GGT) was present in tis-
sues that were believed to actively transport AA [10,11]. Such
tissues include: the brush border of the proximal convoluted
tubules of kidney [12], lactating mammary glands [13], the api-
cal portion of the intestinal epithelium [14], the choroid plexus
[15], and the BBB [16]. An alternative theory, proposed by
Vin˜a et al. [8,9] is that pyroglutamate, which is produced inside
cells as part of the GGC, acts by stimulating Na+-dependent
AA transport and thereby the uptake of AA.
GGT is found in the BBB [16] on the luminal membrane [17].
Lee et al. studied the activity of pyroglutamate on Na+-depen-
dent system A (a transporter of small neutral, non-essential
AA) and found that 2 mM pyroglutamate inside membrane
vesicles increased the rate of transport by 50% [18], supporting
the role of pyroglutamate as a regulator of AA transport.
Because of the importance of glutamate, we studied the eﬀect
of pyroglutamate on Na+-dependent glutamate transport. The
measurements, made on membrane vesicles isolated from the
BBB, indicated that pyroglutamate can stimulate glutamate
removal from brain.2. Materials and methods
2.1. Materials
All radiolabeled isotopes were bought from American Radiolabeled
Chemicals Inc. (St. Louis, MO). Collagenase Type IA and Protease
Inhibitor cocktail were bought from Sigma (St. Louis, MO).
2.2. Animals
Fresh bovine brains were bought from Strauss Veal & Lamb Inter-
national Inc. (Franklin, Wl). The cows were killed for food under
USDA supervision (establishment number 2444) and the brains sold
for human consumption.ation of European Biochemical Societies.
Fig. 1. Na+-dependent uptake of glutamate is stimulated by internal
pyroglutamate. Net transport of [3H] glutamate (0.2 lM) was mea-
sured in abluminal vesicles preloaded with 2 mM pyroglutamate.
Triangles represent controls (no pyroglutamate) and squares represent
vesicles preloaded with pyroglutamate. The dashed lines indicate initial
rates. An inwardly directed Na+ gradient was used in each trial (initial
external Na+ was 126 mM and internal was 0). Net Na+-dependent
transport was corrected for facilitative transport by substituting
choline+ for Na+. The calculated transmembrane potential was
61.5 mV (140 mM K+ inside, 14 mM K+ outside). All values are
means of seven individual determinations ± S.E.
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Membrane vesicles from the brain endothelial cells were prepared as
previously described [19]. Brieﬂy, isolated microvessels from bovine
cerebral cortices were obtained by the method of Pardridge et al.
[20]. The microvessels were digested with collagenase Type IA to sep-
arate the basement membrane, pericytes, and glial fragments, and cen-
trifuged at 5000 · g for 10 min. Pericytes and other debris remain in
suspension. The digested microvessels were suspended in buﬀer
(10 mM Tris, 0.1 mM EDTA, 250 mM sucrose, 0.5 mM MgCl2 and
0.1 ml/l Protease Inhibitor Cocktail) and homogenized with an IKA-
Euroturrax T-20 Standard (Wilmington, NC) for 45 s at setting 6.
The homogenized capillaries were centrifuged at 5000 · g for 15 min
to remove unbroken cells and other large fragments. The supernatant
was centrifuged at 20000 · g for 60 min to pellet the plasma mem-
branes. No further puriﬁcation of cytoplasmic membranes was neces-
sary to study Na+-dependent transport because these transporters are
only found on abluminal membranes [17,19,21–28].
For some experiments on facilitative glutamate transport the luminal
membranes were isolated by centrifugation (175000 · g for 2.5 h) on a
discontinuous Ficoll gradient (0% and 5%) [19]. Luminal membranes
accumulate at the interface while abluminal membranes are pelleted.
2.4. Measurement of transport rates
Rates of transport were measured by rapid ﬁltration [19]. Membrane
vesicles were thawed, centrifuged at 30000 · g for 30 min at 4 C and
suspended in 140 mM KCl, 20 mM HEPES, pH 7.4, with or without
2 mM pyroglutamate. The vesicles were allowed to equilibrate over-
night at 4 C. The ﬁnal concentration of protein was between 5 and
10 lg protein/ll. The vesicle suspensions were divided into 10 ll ali-
quots that were pre-incubated at 37 C for 1 min before initiation of
transport measurements.
Measurements were initiated by the addition of 90 ll of reaction
solution (140 mM NaCl and 20 mM HEPES, pH 7.4, at 37 C) con-
taining [3H] labeled substrate to 10 ll of vesicle suspension. The extra-
vesicular NaCl at the start of the measurements was 126 mM and the
internal concentration was 0. A transmembrane potential was created
by a 10:1 ratio of internal (140 mM) and external (14 mM) concentra-
tions of K+; this was calculated by the Nernst equation to be 61.5 mV
(inside negative) at 37 C [29]. Na+-independent transport was deter-
mined by substituting choline+ for Na+.
Reactions were stopped by adding 1 ml of 4 C stopping solution
(145 mM NaCl and 10 mM HEPES, pH 7.4) and ﬁltered on a
0.45 lm Millipore membrane ﬁlter (Fisher, Pittsburg, PA) under vac-
uum. The ﬁltered membranes were washed three times with 1 ml ali-
quots of stopping solution, after which the ﬁlters were counted by
liquid scintillation spectroscopy. All rates were corrected for non-spe-
ciﬁc transport, binding or trapping as measured at time 0.
2.5. Determination of kinetic characteristics
Initial rates of transport were calculated by measuring the uptake of
[3H] substrate over time. From this non-linear regression analyses (Sig-
ma Plot, SPSS, Chicago, IL) ﬁtted the data to the equation: up-
take = a(1  e-kt). The products of the constants a and k represented
the initial rate. Data were expressed as clearance (permeability-to-sur-
face area products), in units of ll min1 mg protein1.
2.6. Protein determination
Protein concentrations were measured using the Bio-Rad Protein
Microassay (Hercules, CA), with bovine serum albumin as the stan-
dard [30].Fig. 2. Na+-dependent uptake of glutamate is inhibited by internal
glutamate. The net transport of [3H] glutamate (0.2 lM) was measured
in abluminal vesicles preloaded with 2 mM glutamate. Triangles
represent controls (no glutamate) and squares stand for vesicles
preloaded with 2 mM glutamate. The dashed lines indicate initial rates.
An inwardly directed Na+ gradient was used in each trial (see legend of
Fig. 1). Net Na+-dependent transport was corrected for facilitative
transport by substituting choline+ for Na+. The calculated transmem-
brane potential was 61.5 mV (140 mM K+ inside, 14 mM K+
outside). All values are means of seven individual determina-
tions ± S.E.3. Results
3.1. Eﬀect of internal pyroglutamate on Na+-dependent
glutamate transport in abluminal membranes
Preloading abluminal membrane vesicles with 2 mM pyrog-
lutamate stimulated glutamate transport by 46% (EAAT sys-
tems) (Fig. 1). Control, vesicles were preloaded with
glutamate. In contrast to pyroglutamate, preloading the vesi-
cles with 2 mM glutamate did not stimulate uptake; to the con-trary the initial rate of glutamate uptake was decreased by 77%
(Fig. 2). Measurement of glutamate uptake in the presence of
2 mM external pyroglutamate had no eﬀect (data not shown).
Therefore, the data showed that internal pyroglutamate stimu-
lated Na+-dependent transport.
3.2. Eﬀect of internal pyroglutamate on other Na+-dependent
transporters
Although the focus of this article is on glutamate transport,
we tested the eﬀect of pyroglutamate on two other AA trans-
port systems to determine its speciﬁcity. We had previously
shown stimulation of System A transport with the presence
of internal pyroglutamate [18]. Internal pyroglutamate also
Fig. 4. Aspartate inhibits facilitative glutamate transport in luminal
membranes. Net uptake of [3H] glutamate (0.26 lM) was measured in
re-puriﬁed luminal membranes in the presence of 2 mM cystine or
2 mM aspartate (external). Cystine did not inhibit glutamate uptake
whereas aspartate decreased uptake by 70%. There was no Na+
gradient. The calculated transmembrane potential was 61.5 mV
(140 mM K+ inside, 14 mM K+ outside). All values are means of seven
individual determinations ± S.E. *P < 0.05.
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ulation of system N (glutamine) activity (Fig. 3).
Identity of the facilitative transport carrier for glutamate in
the luminal membrane. There are two types of Na+ indepen-
dent carriers described: xAG, which carries glutamate and
aspartate, and xC, which exchanges glutamate for cystine
[31]. Benrabh and LeFauconnier examined the transport of
glutamate in vivo in experiments where they presented gluta-
mate to the luminal surface of the BBB [32]. They determined
the carrier to be xAG. Lee et al. found facilitative glutamate
transport to be located on the luminal membrane only [7].
To distinguish between the two we measured glutamate
transport in luminal membranes as shown in Fig. 4. The inclu-
sion of external cystine (2 mM) did not inhibit glutamate trans-
port whereas 2 mM aspartate decreased uptake by 70%. As
illustrated in Fig. 5, vesicles preloaded with 2 mM cystine,
which might have been expected to accelerate glutamate trans-
port, did not [32]. Therefore, we found no support for the pres-
ence of the glutamate–cystine exchanger xC and conﬁrmed that
the glutamate carrier on the luminal membrane is xAG.
3.3. Eﬀect of internal pyroglutamate on facilitative glutamate
transport in luminal membranes
Luminal membrane vesicles were preloaded with 2 mM
pyroglutamate and facilitative glutamate transport was mea-
sured using choline+ in place of Na+. Internal pyroglutamate
inhibited the facilitative uptake of glutamate (Fig. 6).4. Discussion
Our current concept of the transport of glutamate across the
BBB is illustrated in Fig. 7. The principal ﬁndings in support of
this concept are: (1) intravesicular pyroglutamate accelerated
the initial rate of abluminal Na+-dependent glutamate uptake
(EAATs) whereas extravesicular pyroglutamate did not, (2)
the presence of intravesicular glutamate reduced the initial rate
of Na+-dependent glutamate uptake, (3) the facilitative carrier
located on the luminal membrane was conﬁrmed to be type
xAG rather than the cystine/glutamate exchanger x

C [32], (4)Fig. 3. Eﬀect of pyroglutamate two other Na+-dependent transporters. Prel
0.09 lM [3H] alanine (system ASC, Panel A). No stimulation of 0.13 lM [3H
ASC and system N were made in the presence of 20 mMMeAlB to block the a
Triangles represent controls (no pyroglutamate) and squares correspond to v
initial rates. An inwardly directed Na+ gradient was used in each trial (see le
transport where choline+ was substituted for Na+. The calculated transmemb
All values are means of seven individual determinations ± S.E.the uptake of glutamate in luminal membranes was inhibited
by intravesicular pyroglutamate, (5) the eﬀect of pyrogluta-
mate was not limited to glutamate because system ASC was
also stimulated and we have previously demonstrated that
pyroglutamate stimulates system A [18]. However, system N
was unaﬀected by pyroglutamate. The results suggest that
pyroglutamate is not only an important intermediate in the
glutathione/GGT cycle but it also stimulates the Na+-depen-
dent removal of glutamate from the ECF while simultaneously
decreasing the serum uptake of glutamate. The combined eﬀect
would increase the eﬃciency of glutamate clearance from the
CNS.
The BBB diﬀers in several ways from most tissues that ac-
tively transport amino acids. First, the BBB is composed of
endothelial, not epithelial cells. Second, there are no Na+-
dependent AA transporters on the luminal surface of the
BBB. Therefore, the BBB is not associated with energy depen-
dent AA uptake from plasma. While brain requires essentialoading vesicles with 2 mM pyroglutamate stimulated the transport of
]glutamine (system N, Panel B) was detected. (Measurements of system
ctivity of system A which also transports alanine and glutamine [7,36].)
esicles preloaded with 2 mM pyroglutamate. The dashed lines indicate
gend of Fig. 1). Net transport was obtained by subtracting facilitative
rane potential was 61.5 mV (140 mM K+ inside, 14 mM K+ outside).
Fig. 5. Internal cystine does not stimulate glutamate uptake in luminal
membranes. Net uptake of [3H] glutamate (0.61 lM) was measured in
puriﬁed luminal membranes. Preloading the vesicles with 2 mM cystine
did not stimulate glutamate uptake. The calculated transmembrane
potential was 61.5 mV (140 mM K+ inside, 14 mM K+ outside).
There was no Na+ gradient. All values are means of seven individual
determinations ± S.E.
Fig. 6. Facilitative transport of glutamate is inhibited in luminal
vesicles preloaded with pyroglutamate. Luminal membranes were
preloaded with 2 mM pyroglutamate, and the facilitative uptake of
[3H] glutamate (0.12 lM) was measured. The circles represent uptake
in the absence of pyroglutamate. The squares correspond to vesicles
preloaded with 2 mM pyroglutamate. The dashed lines indicate initial
rates. There was no Na+ gradient. The calculated transmembrane
potential was 61.5 mV (140 mM K+ inside, 14 mM K+ outside). All
values are means of seven individual determinations ± S.E.
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facilitative transport systems that seem to provide only the
amount needed. The adult brain is not growing and it is diﬃ-
cult to detect arteriovenous diﬀerences of AA across the brain
[33–35]. It has, therefore, been puzzling why brain capillaries
have such high GGT activity.
As mentioned, GGC is unlikely to mediate AA transport
directly, but its activity does seem to inﬂuence AA transport
systems indirectly [8,9]. Speciﬁcally, it appears that pyrogluta-
mate, produced intracellularly by GGC, acts to activate the
Na+-dependent systems thereby stimulating the translocation
of AA into these tissues.
Pyroglutamate did not stimulate the Na+-dependent system
N, which is responsible for the transport of glutamine. This isFig. 7. The eﬀect of pyroglutamate on Na+ dependent glutamate transport sy
of glutamate removal from brain ECF, and inhibits the facilitative XAG syste
blood.in contrast to the mammary gland in which pyroglutamate
stimulates glutamine transport [8,9]. Interestingly, glutamine
is the only AA in brain ECF that has a similar concentration
to that of plasma. All other AA are present in concentrations
at about 10% those of the plasma [2]. Thus, glutamine appears
to be treated diﬀerently.
In conclusion, our data support the hypothesis that GGC is
at least part of a control mechanism that inﬂuences the concen-
tration of glutamate in the brain ECF through the generation
of pyroglutamate (Fig. 7). This activity may provide a short-
term regulatory mechanism by which the removal of this
potentially deleterious AA is accelerated. Furthermore, it sug-stems. Pyroglutamate stimulates the EAAT systems, increasing the rate
m, reducing the return of glutamate into the endothelial cells from the
4386 R.A. Hawkins et al. / FEBS Letters 580 (2006) 4382–4386gests that EAAT transporters on the BBB may serve as a ther-
apeutic target in circumstances where glutamate cytotoxicity
occurs, e.g. ischemia or traumatic brain injury. Stimulation
of EAAT transporters by pyroglutamate or comparable mole-
cules during reperfusion could promote the restoration of glu-
tamate homeostasis and reduce the development of cerebral
infarcts.
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